The Ledger

Every statement that passed quotation and attribution checks. Mix any filter with any other: certainty 1/5, debate potential 5/5, or both at once.

clear all ✕

why aren't all 6 resolved? a statement only gets an assessment when the public record can support or contradict it. opinions and what-ifs never can, and 0 checkable ones are still open, waiting for their date. predictions held up or didn't; assertions are supported or contradicted. on every card: ▮▮▮▮▮ certainty · ▮▮▮▮▮ debate potential. speakers are clickable

Opinion
Hims bends rules because GLP-1 cash outweighs risks, says Hays
“Yes, of course they're bending the rules around compounding and like, but they seem to be okay with that risk appetite because they're printing so much cash off of this that they're like, it's one of those situations where they're like, even if we get, you kno…”
Jordi Hays Feb 12, 2025 ▶ 4:48 REVIEW: HIMS Super Bowl Ad (Controversy)
Prediction Held up
Coogan: Novo Nordisk supply will eventually severely limit compounded GLP-1s
“It may take a few more quarters, but Novo Nordisk will eventually produce enough supply to end the shortage of its drug. When that happens, despite their efforts to influence public opinion, Compounded versions will likely be severely limited.”
John Coogan Feb 12, 2025 ▶ 14:23 REVIEW: HIMS Super Bowl Ad (Controversy)
Opinion
Coogan: Hims Might Be Most Successful DTC Company Beside Chewy
“At ten billion dollars, it might be literally the most successful DTC company other than maybe Chewy to come out, but even that's more of an e-commerce platform.”
John Coogan Feb 12, 2025 ▶ 3:36 REVIEW: HIMS Super Bowl Ad (Controversy)
Insight
Coogan: Telehealth compounding stretches regulations meant for local pharmacies
“Compounding pharmacy regulations were written for, hey, your town might have a local pharmacist, and in a shortage, you should be able to walk down to the pharmacy, and they should be able to make you know, something that they can't otherwise buy, and then thi…”
John Coogan Feb 12, 2025 ▶ 12:42 REVIEW: HIMS Super Bowl Ad (Controversy)
Assertion Supported
Coogan: Hims & Hers drops record 32% after Novo Nordisk split
“News that the deal was scrapped weighed heavily on Hims and Herb's shares, sending them down 32% in afternoon trading in what would be the largest decline for the stock on record. Novo Nordisk's shares were down nearly six percent in New York.”
John Coogan Jun 28, 2025 ▶ 1:17:50 Weekly Recap: Tesla Robotaxi, Mr. Beast's AI Tool, Yacine, The Social Network 2, Neuralink Update
Assertion Supported
Hays: Hims & Hers has nearly 100,000 weight management subscribers
“They have a broader weight management offering. I think they have multiple products, but they have nearly a 100,000 subscribers. So that could be why they have the stock's been ripping”
Jordi Hays Nov 19, 2024 ▶ 1:10:08 Who's Getting Rich Off Ozempic? (e12)
Made with StarZero

Turn any episode into a week of clips.

This entire site, over 500 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.